Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

197

Citations

32

References

2013

Year

Leena Gandhi, Rastislav Bahleda, Sara M. Tolaney, Eunice L. Kwak, James M. Cleary, Shuchi S. Pandya, Antoine Hollebecque, Richat Abbas, Revathi Ananthakrishnan, Anna Berkenblit,

Journal of Clinical Oncology

Abstract

The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor activity in multiple tumor types, warranting further evaluation.

References

	Year	Citations

Page 1